Skip to main content
. 2016 Sep 22;40(4):468–475. doi: 10.2337/dc16-0985

Figure 1.

Figure 1

Age- and sex-standardized proportion of patients with T2DM who filled each class of glucose-lowering agents, 2006 and 2013 (see Supplementary Table 2 for annual data). Since patients may fill more than one class in each year, percentages do not add up to 100%. Other medications were comprised of meglitinides, α-glucosidase inhibitors, SGLT-2 inhibitors, and amylin analogs. Patients with no fills for glucose-lowering medications were included in the “No medications” group.